Results 51 to 60 of about 18,542 (210)
Medicinal Research Reviews, EarlyView.ABSTRACT Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive impairment, memory deterioration, and neuronal dysfunction. Its complex pathophysiology involves multiple interlinked processes, including amyloid‐β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation ...
Amandeep Thakur +6 more
wiley +1 more source
Turkish Journal of Agriculture: Food Science and Technology, 2019 The aim of this study was to determine the effect of different doses and combinations of benzylaminopurine (BAP) and Putrescine elicitor on some plant characteristics of summer snowflake (Leucojum aestivum L.).
Mehmet Uğur Yıldırım +5 more
doaj +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen +3 more
wiley +1 more source
Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
Clinical Interventions in Aging, 2009 Ben SeltzerGeriatric Research, Education and Clinical Center, VA Boston Healthcare System, Department of Neurology, Harvard Medical School, Boston, MA, USAAbstract: An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine ...
Ben Seltzer
doaj
Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis [PDF]
, 2003 Background Cholinesterase inhibitors, such as galantamine, donepezil and rivastigmine are approved for symptomatic treatment of Alzheimer's Disease (AD) in Canada. In making choices amongst these drugs, one should consider their clinical merits and their
Jaime Caro +5 more
core +2 more sources
Dementia Risk in Type 1 and 2 Diabetes: A Nationwide Population‐Based Comparison
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Diabetes is increasingly recognised as a major contributor to cognitive decline and dementia, but the risk varies by diabetes type and treatment intensity. We compared the risk of all‐cause dementia, Alzheimer's disease (AD) and vascular dementia (VaD) among individuals with and without diabetes.
Ji Eun Jun +3 more
wiley +1 more source
Journal of the American Geriatrics Society, EarlyView.ABSTRACT Background Prescribing cascades occur when cholinesterase inhibitor (ChEI)‐induced urinary incontinence is misinterpreted as a new condition, leading to overactive bladder (OAB) antimuscarinic initiation. We evaluated whether the ChEI‐OAB antimuscarinic prescribing cascade was associated with delirium or falls compared with mirabegron in older
Sarah Beth Tucker +9 more
wiley +1 more source
Frontiers in Pharmacology, 2021 Patient’s poor compliance and the high risk of toxic effects limit the clinical use of galantamine hydrobromide. To overcome these drawbacks, the sustained-release galantamine pamoate microspheres (GLT-PM-MS) were successfully developed using an oil ...
Liping Du +8 more
doaj +1 more source
Journal of Sleep Research, Volume 34, Issue 2, April 2025.Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont +5 more
wiley +1 more source